Loading…
← CockpitCompetitor Analysis › DYN Dyne Therapeutics IncOpen in the cockpit ↗

Dyne Therapeutics IncDYNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops oligonucleotide therapies delivered directly to muscle tissue for muscular dystrophies and myotonic dystrophy.

Momentum weak 25
Mkt cap
$2.97B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$41.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.7%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$15.87
1D-0.9%
1W-11.8%
1M-2.5%
3M-38.9%
6M-9.6%
YTD-18.9%
1Y-21.6%
ATR %5.8%
Beta1.76
52w lowhigh41.9% off high

What Dyne Therapeutics does

Develops oligonucleotide therapies delivered directly to muscle tissue for muscular dystrophies and myotonic dystrophy.

Has no product on the market, so operations are funded by selling shares to investors, and each trial result sets how easily it can raise more money. Any later income would come from selling approved therapies itself or through partners.

Products and services

  • DYNE-101 (myotonic dystrophy type 1)
  • DYNE-251 (Duchenne muscular dystrophy)

Customers

  • Neuromuscular disease specialists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Muscle-targeted oligonucleotide…

What could go right

  • Pivotal trial data readouts
  • Muscle-delivery platform expansion to new targets

What could go wrong

  • Clinical trial failure risk
  • Competitive muscular dystrophy field

Moat: narrow (IP / patents, process know-how). Proprietary FORCE muscle-targeting delivery platform for oligonucleotides, though still clinical-stage.

Headquarters: Waltham, Massachusetts, US · Founded: 2017 · Employees: 258

Named competitors

Dyne Therapeutics at a glance

Size Dyne Therapeutics (DYN) is a United States Health Care company (Biotechnology) with a market value of $2.97B, the 1549th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.87 on 18 Nov 2026.

Performance Over six months the shares fell 9.6%, against +2.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Short interest Short interest is 13.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026Peer median 103DYN 91
Six months, rebased to 100: Dyne Therapeutics against the median of its 20 peers (local-currency closes).

Dyne Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$2.27M-$2.05M-$2.24M-$2.46M-$3.35M
EBITDA-$618M-$466M-$342M-$240M-$168M
Net income-$605M-$446M-$317M-$236M-$168M
Free cash flow-$569M-$424M-$295M-$189M-$157M
Capital expenditure$4.23M$20.7M$2.38M$729,000$3.07M
Total debt$244M$169M$24.0M$27.4M$30.5M

Quarterly statements and history in the cockpit →

Dyne Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%TLXDNLIRUBICONADMA2228XERSBAVA9688VIRP6887028300ELVNMBXXNCR688278IOVADYN6-month return →1-month return →
Up and to the right = strong over both horizons. Dyne Therapeutics is the large dot.

Dyne Therapeutics competitors and peer comparison

Head to head with its named competitors (DYN vs SRPT vs IONS vs WVE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Dyne Therapeutics DYN$2.97B-10%n/an/an/an/a
Sarepta Therapeutics SRPT$1.56B-15%-19%0%0.9×-6.8%
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
Wave Life Sciences WVE$546M-55%-35%-321%2.2×n/a
Entrada Therapeutics TRDAn/a-17%n/an/an/an/a
Solid Biosciences SLDB$709M-2%n/an/an/an/a
Nippon Shinyaku 4516.T$1.42B-20%+18%18%0.8×-18.1%

How Dyne Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dyne Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDYNPeer medianRank in peer set
1-month return-2.5%-3.3%10th highest of 21
6-month return-9.6%+2.8%7th lowest of 21
Distance from 52-week high-41.9%-27.8%6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a

Questions

Who are Dyne Therapeutics's main competitors?
Named competitors: Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Avidity Biosciences (private or unlisted), PepGen (private or unlisted), Wave Life Sciences (WVE), Entrada Therapeutics (TRDA). The cockpit's measured peer set (industry) also includes Telix Pharmaceuticals (TLX.AX), Denali Therapeutics (DNLI), Rubicon Research (RUBICON.NS), ADMA Biologics (ADMA), XtalPi (2228.HK), Xeris Biopharma (XERS).
How has Dyne Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -9.6% against +2.8% for the median peer; over one year -21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.